Track topics on Twitter Track topics that are important to you
Lundbeck and Otsuka are seeking to extend their US licence for Abilify for use in bipolar disorder. Currently approved in schizophrenia, the companies have asked the FDA to expand the label of Abilify Maintena (aripiprazole), to include maintenanc...
Original Article: Lundbeck/Otsuka look for new use of mental health drugNEXT ARTICLE
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...